Literature DB >> 6752032

Type-specific protection of neonatal rats from lethal group B streptococcal infection by immune sera obtained from human volunteers vaccinated with type III-specific polysaccharide.

B J De Cueninck, T K Eisenstein, T S McIntosh, G D Shockman, R M Swenson.   

Abstract

Sera obtained from human volunteers at 6 weeks after vaccination with highly purified type III polysaccharide antigen prepared from a group B Streptococcus, strain M732, were found to protect neonatal rats from otherwise lethal infection by the homologous strain. The specific antibody content of the sera, expressed in micrograms of antibody protein per milliliter, was determined by an enzyme-linked immunosorbent assay in conjunction with quantitative precipitin analysis. For two sera studied in detail, the protective dose of antibody for 50% of the animals was 0.4 micrograms. Immune serum obtained from a volunteer who received type II polysaccharide vaccine was not protective against type III infection. Absorption of anti-type III serum by quantitative precipitation of antibodies with type III polysaccharide completely removed the passive protective activity of the serum. The results show that antibodies induced in humans by purified type II polysaccharide give serotype-specific protection in an animal model of neonatal infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6752032      PMCID: PMC347632          DOI: 10.1128/iai.37.3.961-965.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

Review 1.  Summary of the workshop on perinatal infections due to group B Streptococcus.

Authors: 
Journal:  J Infect Dis       Date:  1977-07       Impact factor: 5.226

2.  Type-specific antigens of group B type Ic streptococci.

Authors:  H W Wilkinson; R G Eagon
Journal:  Infect Immun       Date:  1971-11       Impact factor: 3.441

3.  Quantitative determination of the human immune response to immunization with meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; R Triau; K J Sparks
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

4.  Soluble group- and type-specific antigens from type III group B Streptococcus.

Authors:  R B Carey; T K Eisenstein; G D Shockman; T F Greber; R M Swenson
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

5.  Human immunity to group B streptococci measured by indirect immunofluorescence: correlation with protection in chick embryos.

Authors:  L C Vogel; R R Kretschmer; K M Boyer; D M Padnos; C A Gadzala; S P Gotoff
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

6.  Antibody to group B Streptococcus type III in human sera measured by a mouse protection test.

Authors:  R S Baltimore; C J Baker; D L Kasper
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

7.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

8.  Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.

Authors:  G W Fischer; G H Lowell; M H Crumrine; J W Bass
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

9.  A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B).

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1934-03-31       Impact factor: 14.307

10.  A SEROLOGICAL DIFFERENTIATION OF HUMAN AND OTHER GROUPS OF HEMOLYTIC STREPTOCOCCI.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1933-03-31       Impact factor: 14.307

View more
  7 in total

1.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

2.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

3.  Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization.

Authors:  Jacqueline A Baker; Emma L Lewis; Leah M Byland; Maryam Bonakdar; Tara M Randis; Adam J Ratner
Journal:  Vaccine       Date:  2017-02-02       Impact factor: 3.641

4.  Identification of major outer surface proteins of Streptococcus agalactiae.

Authors:  Martin J G Hughes; Joanne C Moore; Jonathan D Lane; Rebecca Wilson; Philippa K Pribul; Zabin N Younes; Richard J Dobson; Paul Everest; Andrew J Reason; Joanne M Redfern; Fiona M Greer; Thanai Paxton; Maria Panico; Howard R Morris; Robert G Feldman; Joseph D Santangelo
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci.

Authors:  B F Anthony; N F Concepcion; C A Wass; D C Heiner
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

6.  Isolation, chemical composition, and molecular size of extracellular type II and type Ia polysaccharides of group B streptococci.

Authors:  B J De Cueninck; T F Greber; T K Eisenstein; R M Swenson; G D Shockman
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

7.  Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus.

Authors:  B J De Cueninck; T K Eisenstein; T S McIntosh; G D Shockman; R M Swenson
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.